Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Consider renal function in TLS risk assessment of venetoclax-treated CLL

Publish date:: October 29, 2019

Key clinical point: Impaired renal function appears to be associated with risk of tumor lysis syndrome (TLS) in venetoclax-treated patients.

Major finding: The area under the receiver operating characteristic curve was 74.6% when creatinine clearance was added to the standard model for assessing TLS risk, compared with 65% for the standard approach.

Study details: A retrospective cohort study of 339 CLL patients.

Disclosures: Dr. Mato has received grant support, consulting fees, and/or fees for serving on a data and safety monitoring board or advisory board from AbbVie, AstraZeneca, Celgene, Janssen, TG Therapeutics, Pharmacyclics, Loxo, Sunesis, prIME Oncology, Pfizer, Johnson & Johnson, and Regeneron.

Citation:

Mato A et al. iwCLL 2019, Abstract 2008.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,